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461: Open source drug discovery for infectious
diseases—a case application on Tuberculosis (Phase I)
1,2Samir K. Brahmachari, 2CSIR-led OSDD Consortium
1Institute of Genomics and Integrative Biology, Mall Road,
Delhi-110007, India, 2Council of Scientific and Industrial Research,
Anusandhan Bhawan, 2 Rafi Ahmed Kidwai Marg,
New Delhi-110001, India
The Human Genome sequence created stir in the scientific community
with the promise to make a remarkable difference to healthcare. With
Mycobacterium tuberculosis genome sequenced 10 years ago we still
lack an effective therapy for tuberculosis. If we have not been able to
solve the TB problem, how can we solve the problems of other
complex human diseases? For life-style diseases, pharmaceutical
companies actively scout advances in basic research in search of new
and potentially lucrative drug targets. For TB, this is not the case.
Early stage drug discovery is the key bottleneck in the pipeline to
novel drugs for tuberculosis. Most public-funded institutions are
involved in a lot of biomedical research but the journey from lead
molecule to market is a ‘close-door’ activity which increases the drug
discovery cost to a great extent. Open Source Drug Discovery
(OSDD) is a CSIR lead initiative with the vision to provide affordable
healthcare to the developing world by providing a global platform
where the best minds can collaborate and collectively endeavor to
solve the complex problems associated with discovering novel ther-
apies for the diseases of the third world countries. Taking cue from
the successes of ‘Open Source approach’ in IT and ‘Human Genome
Project’, there is an urgent call for such a programme in healthcare.
The OSDD concept aims to bring in the power of genomics, com-
putational technologies and participation of young and brilliant talent
from Universities and industrial partners. In this context, the devel-
opment of OSDD portal is a key deliverable of the project. It will be
the source of interaction among scientists and their peers, of storing
data and retrieval, of analysis of biological systems through algo-
rithms to name a few. Research problems demanding innovations will
be posted. Users both from within and from outside the project
community will be allowed to participate and appropriate prizes will
be announced for the best solutions. The project ‘Open Source Drug
Discovery’ conception envisions the participation of scientists and
students in growing numbers as the momentum of the Open Source
movement grows. Private companies are becoming conscious of their
social responsibility and many would like to join such initiatives.
OSDD project is committed to provide world class portal in Open
Source mode to build and coalesce user community including tapping
intelligent minds for affordable drug development for M. tuberculosis
and will be presented in detail.
462: Testing SNP markers for human identification
application
Jianguo Chen, Driguneswar Pinnamaneni, Shravan Kumar
Komaragiri, LaQuana Martino, Cherrelle Wright
Claflin University, Orangeburg, SC 29115, United States of America
Developing a detection system for degraded DNA samples presents a
big challenge for the field of DNA-based human identification. Cur-
rently commercial human DNA identification methods are based on
the use of short tandem repeat (STR) DNA markers. Applied Bio-
systems’AmpF/STR Identifier and Promega’s PowerPlex 16 systems
for human identification generate the STR PCR fragments up to 370
base pairs and 470 base pairs, respectively. When DNA samples are
degraded, however, neither kit is able to generate the PCR products
required for the identification. We investigated the use of single
nucleotide polymorphism (SNP) markers for human identification. In
the SNP approach much shorter DNA fragment are required, this will
allow the system to work on degraded DNA samples. We select SNP
markers with allele frequencies ranging from 0.35 to 0.5 among the
Asian, African and Caucasian populations and test these markers on
DNA samples from these populations. We calculated that 50 SNP
markers can provide discrimination power of about one thousand
trillion, so the odds that two individuals will have the same 50 SNP
DNA profiles are about one in one thousand trillion. The discrimi-
nation power from 50 SNP is much higher than the current
commercial products. Another advantage of SNP technology is that
the SNP probes can be put on DNA chip or array platform. We test
SNP markers on the DNA samples from Asian, African and Cauca-
sian populations and are looking for the SNP markers which have
desired allele frequencies cross all the human populations. Some SNP
markers showed desired allele frequencies among all the population
and some SNP markers only for certain population. This information
is valuable for the SNP Human Identification technology
development.
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463: Enhanced workflow for sequencing PCR products
by capillary electrophoresis
Colin Davidson, Samar Lightfoot, Sreeram Santhanam,
Andrew Felton, Eric Vennemeyer, Erica Currie-Fraser, Paul Kotturi,
Meri Bozzini, Hanh Le, Shiyi Pickrell, Peter McNamara,
Ste´phane Jankowski, Licen Xu
Applied Biosystems, 850 Lincoln Centre Drive, United States
of America
Since the introduction of Sanger dideoxy sequencing, significant
efforts have been directed toward increasing throughput by stream-
lining workflow. We describe here further enhancements for a PCR
product resequencing workflow capable of reducing the total time,
from beginning PCR reactions through completion of basecalling,
to *4 h. The workflow shown employs a new AmpliTaq Gold Fast
PCR Master Mix in conjunction with modified thermal cycler con-
ditions to substantially reduce the time required for PCR
amplification. Process time is further reduced through optimization of
cycle sequencing conditions (BigDye Terminator v1.1 Cycle
Sequencing Kits). We have coupled these improvements with an
efficient sequencing reaction cleanup protocol and decreased Capil-
lary Electrophoresis (CE) run time using MicroAmp Fast 96-Well
Reaction Plates on an Applied Biosystems 3130 xl Genetic Analyzer.
Overall data quality compares favorably with data obtained using
previously documented methods. The increased efficiency and gen-
eration of high-quality results is vital to numerous research
applications in reducing time for screening and validation.
464: ERa-bound chromatin interactions are prevalent
and functional in the human breast cancer genome
1,2Melissa J. Fullwood, 1Jun Liu, 1Hong-Sain Ooi, 1You Fu Pan,
1Han Xu, 1Mei Hui Liu, 1Vinsensius B. Vega, 1Yanquan Luo,
1K. D. Senali Abayratna Wansa, 1Pramila N. Ariyaratne,
1Andrea Chavasse, 1Bing Zhao, 1Kar Sian Lim, 1Shi Chi Leow,
1K. R. Govindarajan, 1Melvyn Tan, 1Yew Kok Lee, 1Haixia Li,
1Phillips Y. H. Huang, 1R. Krishna Murthy Karuturi,
1Kartiki V. Desai, 1Jane S. Thomsen, 1Thoreau Herve,
1Guillaume Bourque, 1Ken W. K. Sung, 1Edison T. Liu,
1Chia Lin Wei, 1,3,4Edwin Cheung, 5Yijun Ruan
1Genome Institute of Singapore, Agency for Science, Technology and
Research, Singapore, 2NUS Graduate School for Integrative Sciences
and Engineering, National University of Singapore, Singapore,
3Department of Biochemistry, Yong Loo Lin School of Medicine,
National University of Singapore, Singapore, 4School of Biological
Sciences, Nanyang Technological University, Singapore,
5Department of Biological Sciences, National University of
Singapore, Singapore
The three-dimensional structures of genomes in vivo are thought to be
functional, but our understanding of chromatin interactions is ham-
pered by a lack of genome-wide methods capable of detecting de
novo interactions. Here we developed and validated the ChIA-PET
method, a genome-wide, high-throughput, unbiased, and de novo
approach for detecting chromatin interactions. Using ChIA-PET, we
characterized ERa-mediated interactions in estrogen-treated human
breast adenocarcinoma cells (MCF-7), generating the first whole
genome interactome map. We detected an unprecedented number of
interactions between ERa binding sites, suggesting that ERa-bound
interactions are a primary mechanism by which ERa functions.
Uncovering these interactions on a genome-wide scale would have
been highly laborious and expensive with previous methods. With this
resource, we showed that ERa-bound interactions are primarily in-
trachromosomal, complex, and functional. Specifically, we found that
ERa-bound interactions are associated with gene activation, PolII
marks, H3K4me3 marks, and FoxA1 binding. Our data offers a par-
simonious mechanism that allows for the maximal sharing of
transcription factors by bringing genomically distant transcription
factor binding sites in ‘cis’ to function in close spatial proximity,
increasing the number of Estrogen Response Elements in interaction
complexes, and increasing the local concentration of factors involved
in transcription such as PolII and inducing H3K4me3 marks, thus
allowing transcription to proceed. We anticipate that the ChIA-PET
method will be a starting point for detailed, whole genome investi-
gations into chromatin interactions, and the extensive set of chromatin
interactions found here will be a rich resource for studies on
chromatin interactions and ERa biology.
465: Novel biomarkers in early stages of lung
adenocarcinoma identified with oligonucleotide based
DNA microarrays
Damjan Glavac, Metka Ravnik-Glavac, Vid Mlakar
Department of Molecular Genetics, Faculty of Medicine, University
of Ljubljana, Slovenia, Vrazov trg 2, Slovenia
Expression profiling analysis of human cancers is a promising
approach for obtaining precise molecular classification of cancers, for
developing stratification tools for therapeutic regimes, and for pre-
dicting survival and disease recurrence. We prepared a 14,640 spot
microrarrays for the expression monitoring of 3,048 genes involved in
tumour development and apoptosis of cancer. The study included 45
patients with operable lung adenocarcinoma. The microarrays were
prepared with 70-mer oligonucleotide sets AROS Human Apoptosis
Subset v2.0 in Human Cancer Subset V3.0 (Operon) by spotting
them to Nexterion Slide E using an MG1000 spotter. Forty genes (32
up-regulated and 8 down-regulated) with differential expression
between N2 and N0 stage lung adenocarcinoma were identified.
Selected up-regulated (SPP1, CLEC3B, TTYH1, RAI1, GATA2,
RBL2, WNT2, KRT19, CRABP2, PMP22, MVP, HOXA4, IGLL1,
MAS1 and CARD10) and down-regulated (CALM3, CD52, HBA2,
CAV1, PRLR, VIPR1, NFKBIA, CYP4B1, VIM and S100A4) genes
were further investigated with real time PCR for expression and copy
number alterations. Losses and/or gains were characteristic of four
genes, indicating that altered expression of those genes is probably
due to copy number variations. Interestingly, a reverse correlation
between SPP1 and VIPR1 expression was also indicated. Down-
regulation of the VIPR1 gene in lung ADs and SCLCs corroborates its
proposed tumour suppressor role. The lack of association between
changes in expression or copy number of the VIPR1 gene with his-
tological data suggests that changes in both expression and copy
number are likely to occur early in AD development. Identification of
the differentially expressed genes in lung cancer may provide better
molecular markers for early diagnosis and identification of novel
intervention sites for anti-cancer therapy.
466: Development of a high-throughput pyrosequencer
with integrated sample preparation
1,2Sanket Goel, 4Peter Griffin, 3Mostafa Ronaghi, 3Ronald W. Davis,
2Dim-Lee Kwong, 1Edison T. Liu
1Genome Institute of Singapore, 60 Biopolis Street, #02-01, Genome,
Singapore 138672, Singapore, 2Institute of Microelectronics, 11
Science Park Road, Science Park II, Singapore 117685, Singapore,
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3Stanford Genome Technology Center, 855 S California Avenue, Palo
Alto, CA, 94304, United States of America, 4Center for Integrated
System, CISX-301, Stanford, CA, 94305, United States of America
The Human Genome Project was essentially accomplished by a
reduction in the cost of DNA sequencing by three orders of magni-
tude. To reduce the cost further and achieve the goal of 1,000 dollars
per genome, a highly integrated platform with a new implementation
of a robust sequencing technology with a proven reputation is needed.
Depelopment of a flexible Superscalar Pyrosequencer to generate
sequence data on mammalian genome in a single run with
209 coverage is underway. Pyrosequencing, a sequencing-by-syn-
thesis method for DNA sequencing, is emerging as a popular platform
for DNA analysis. It relies on the bioluminometric real-time detection
of inorganic pyrophosphate (PPi) released on successful incorporation
of nucleotides during DNA synthesis. Here, 1 pmol of DNA template
can generate more than 6 billion photons at a wavelength of 560 nm,
which can be easily detected. An inexpensive lab-on-a-chip platform
integrated with CMOS image sensors is leveraged to perform
pyrosequencing. This will enable any lab to perform de novo genome
sequencing. To reach this goal, significant improvements have been
made in the chemistry, microfluidic device fabrication, base-calling,
assembly, and detection parts. We will present results from the first
generation of our device, where the Pyrosequencing analysis will take
place inside nanofluidic fiberoptic faceplates. First, a picolitre sized
50 micron wells are fabricated by SU-8 photolithography on fiber-
optic faceplates. The DNA fragments and enzymes are immobilized
on 30 micron sepharose beads and 2 micron paramagnetic beads,
respectively. The beads are centrifuged into the SU-8 wells resulting
only one DNA bead per well. The final device is integrated by pitch-
matching wells on picotiterplate to pixels of an inexpensive and
custom designed CMOS image sensor. A microfluidic flow-system
consisting of a valve selector and peristaltic pump is designed to
direct the reagent from one of the seven input reservoirs to the inlet of
the device. The 50 mm 9 2 mm region of the device is capable to
sequence more than one million bases. To automate the whole system,
a new scheme for template preparation will also be presented. The
end result of this joint effort project will be an integrated Pyrose-
quencing machine enabling sequencing of 3 Gigabase of de novo
genome in a single run for \1,000 dollars.
467: The evolution of a high-capacity, multi-user
sample management network
Michael Hogan
GenVault Corporation, 6190 Corte Del Cedro, Carlsbad, CA,
United States of America
GenVault develops technology to simplify and reduce the cost of
biological sample management. They were the first to conceive of
high-density archives based on room temperature storage and the
automated recovery of discrete bits of air-dried specimen material. A
number of products are now based on that dry-state focus: including
manual and automated hardware devices to organize room-tempera-
ture sample handling for a few hundred up to a few million
specimens; a robust sample management software system; a chemical
bar code that can be used to tag each air-dried sample internally;
dry-state biological sample storage on treated paper disks in a 384
well plate format; a processing chemistry that enables the complete
release of native DNA from dried tissue stored on such paper or other
porous material; and finally, the development of non-paper, dry state
storage media based on ceramics and porous, sponge-like elastomers.
Those new storage matrices greatly extend the mass, volume and the
type of bio-sample that can be stored in the air-dried state. Those
various dry-state storage technologies will be briefly reviewed, indi-
vidually. However, more importantly, GenVault has found a way to
integrate those several dry-state sample storage technologies into a
system that links both the (new) dry-state sample management
approaches with (the best existing) methods of refrigerated sample
management. That integrating technology, referred to as the Dynamic
Archive System, allows DNA and protein (in both the refrigerated and
dry-state) to be collected and managed in parallel, with information
technology to coordinate sample acquisition and sample sharing
among multiple sites. A timely example, for the largest-scale exten-
sion of that Dynamic Archive technology, will be discussed here,
from the nation of Canada, who have recently announced completion
of a multimillion-dollar national genetic archive located in Quebec.
This ‘Chicoutimi Biobank’ allows highly regulated sample collection,
storage and retrieval from sites throughout Quebec, to be shared
internationally among the Public Population Project in Genomics
(P3G) consortium, and with enough capacity to support several dec-
ades of robust sample collection and sharing. It is proposed that, with
minimal site-specific modification, such Dynamic Archives could
serve as a flexible infrastructure standard for population-scale
genetics and proteomics, among large (and small) biobanks currently
being developed throughout North America, Europe and Asia.
468: Human whole genome sequencing
by high-throughput, short read oligonucleotide ligation
1F. C. L. Hyland, 1F. M. De La Vega, 2H. E. Peckham, 2S. S. Ranade,
2S. F. McLaughlin, 2C. C. Lee, 2Y. Fu, 1Z. Zhang, 1R. Koehler,
2C. R. Clouser, 2A. A. Antipova, 2J. M. Manning, 2C. L. Hendrickson,
2L. Zhang, 2E. T. Dimalanta, 2T. D. Sokolsky, 2 M. W. Laptewicz,
2B. E. Coleman, 2J. K. Ichikawa, 2J. B. Warner, 1B. Li, 3A. Bashir,
3 V. Bansal, 3V. Bafna, 2G. L. Costa, 2K. J. McKernan
1Applied Biosystems, Foster City, CA, USA, United States of
America, 2Applied Biosystems, Beverly, MA, USA, United States of
America, 3Dept of Computer Science University of California, San
Diego, CA, USA, United States of America
The advent of new ultra-high throughput sequencing methods allows
contemplation of resequencing thousands of human genomes to
extensively survey common and rare forms of genetic variation that
could have implications in health and disease. We sequenced the
genome of an individual of African origin with the Applied Biosys-
tems SOLiDTM system. The method allows sequencing of single or
paired ends 25–50 bp reads of 108–109 templates on a single array
containing beads with clonally amplified templates. We collected
over a billion reads in 7 runs, amounting to a total of 32 Gbp of
sequence, and obtained an average 129 haploid sequence coverage
and 1309 clone coverage. After aligning those reads to the hg18
reference assembly, over 95% of the genome is covered and 99.45%
of the genome is spanned by a paired end clone. A novel error cor-
rection technique improves the accuracy of the aligned reads
to [99.95%. With such accuracy, our results suggest that heterozy-
gote identification can be efficiently achieved at 10–159 coverage
levels, by comparison with known HapMap genotypes. We detected
over 2 million SNPs, of which 81.4% are in dbSNP. We categorize
the genes using the Panther ontology, and annotate the damaging
potential of non-synonymous SNPs using PolyPhen. We discovered
that transcription factors, ligases, growth factors, receptors, and RNA
helicases are the molecular functions most under-represented for
damaging mutations, and GPCR genes involved in Olfaction, and
genes for Immunity and defense are the biological functions most
over-represented for damaging mutations. Olfaction and Immunity
have previously been observed to be under recent positive selection in
Genomic Med. (2008) 2:381–388 383
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human populations; thus we recapitulate evidence of natural selection
in a single human sample. About 90,000 small insertions and dele-
tions (\12 bp) were identified with the use of paired end reads. Indels
are significantly underrepresented in translated exons. The analysis of
the distance and orientation of the paired end reads allowed the
identification of thousands of putative insertions and deletions ranging
from 50 bp to several Kb. We predict 50 inversions (25% previously
reported in other samples) and four gene fusions resulting from
deletions (two previously reported). Depth of coverage analysis
allows the inference of copy-number variants. Our results provide
guidance for future studies to discover sequence and structural vari-
ants in human populations and cancer with short-read next generation
sequencing.
469: Evaluation of factors affecting the success
of multiplex PCR
Lauris Kaplinski, Maido Remm
Institute of Molecular and Cell Biology, University of Tartu, Riia 23,
Tartu 51010, Estonia
A set of 200 genomic PCR primers was tested in multiplex experi-
ments. All primers were working flawlessly in single-plex
experiments, as determined by gel electrophoresis. In multiplex
environment about 5% of 2-plex experiments and 25% of 4-plex
experiments failed to produce at least one of expected PCR products.
By using statistical model we determined the factors that have cor-
relation with the degradation of the quality of multiplex PCR. The
most important factor was the number of possible alternate genomic
binding sites of primers, as determined by nearest-neighbour ther-
modynamic model. The same factor is also correlated with the
degradation of the quality of single-plex PCR, but the effect is much
stronger in multiplex conditions. We also found, that the hybridiza-
tion affinity between primers of different PCR, calculated by nearest-
neighbour thermodynamic model, is correlated with the degradation
of the quality of multiplex PCR, although the effect is much lower
than the effect of genomic hybridization. These results can be used in
the design process of primers for multiplex PCR. Lower quality
primers can be eliminated already in design phase. Additional testing
for unwanted hybridization between different PCR primer pairs can
be used as criterion in designing multiplex groups.
470: The potential of RNA interference—an overview
Akshat Khanna
Vellore Institute of Technology University, Vellore, India
The recent discoveries of RNA and RNAi have revolutionized our
understanding of gene regulation. RNAi, with its high specificity,
limited side effects, can be used as a tool to control the expression of
specific genes and has potential as a therapeutic strategy to reduce the
expression of unwanted genes. Being an area of intense, upfront
research, it is proving to be useful to analyze quickly the functions of
a number of genes and even mutations in a wide variety of organisms.
RNAi has established a novel paradigm with far-reaching conse-
quences in the field of regulation of transcription, including the study
of many common and uncommon genetic disorders. The major
challenge in turning RNAi into an effective therapeutic strategy is the
delivery of its agents like synthetic double stranded RNAs to the
target cells in mammalian body, which induces a set of different
antiviral responses with the production of interferons that limits the
ability of a virus to replicate further to carry out the mechanism of
silencing. This challenging task of RNAi delivery can be dealt with
methodology like viral vectors - Retrovirus, Lentivirus, Adenovirus,
Adeno-Associated-Virus (AAV), and Baculovirus or by SNALP—
stable nucleic acid-lipid particles or by particulate carriers like
polyethyleneimine (PEI) or even by some modified bacterial carriers.
Once this challenge is met then it will accelerate discoveries and
deepen our existing knowledge on the whole genome. RNAi may
facilitate drug screening and development by identifying genes that
can confer drug resistance, providing information about the modes of
action of novel compounds. It will be possible to find targets for
various diseases ranging from oncogenes to growth factors and single
nucleotide polymorphisms (SNPs), Hepatitis B, C virus and even HIV
virus have also been important targets for potential RNAi therapy.
The potency and potential therapeutic utility of RNAi is pumping
renewed vigour into delivery-related research and this technology is
expected to be the most soughtful treatment for the upcoming
generations.
471: A new assay in functional genomics: monitoring
cell differentiation in live cell chips
by electric cell-substrate impedance sensing
1,2Christian Maercker, 3Dirk Breitkreutz, 4Armin Bieser,
5Karen Bieback, 2Michael Angstmann
1German Cancer Research Center, Core Facilities Genomics and
Proteomics, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany,
2Mannheim University of Applied Sciences, Paul Wittsack Strasse 10,
68163 Mannheim, Germany, 3German Cancer Research Center,
Heidelberg, Germany, 4ibidi GmbH, Martinsried, Germany, 5Institute
for Transfusion Medicine and Immunology, University of Heidelberg,
Mannheim, Germany
There is a great demand for cell-based in vitro screening systems for
drug target validation and generation of resources for cell therapies.
Our assay is focused on the formation of contacts between cells and
between cells and the extracellular matrix, which is important for cell
differentiation processes relevant in cancer therapy and tissue repair.
Cellular interactions are measured with a method called electric cell-
substrate impedance sensing (ECIS). By applying alternating current
and measuring the voltage across an electrode, the impedance can be
calculated and broken down into a series resistance and capacitance.
Insulating membranes of spreading cells block and constrain the
current flow, resulting in measured variations in the impedance. We
showed the applicability of this system with different cell types and
chip designs (Maercker et al. Eng Life Sci (2008) 8, 1–8). Mesen-
chymal stem cells (MSCs), isolated from bone marrow, were
transferred to a specialized multi-well live cell chip with integrated
electrodes which allowed us to measure cellular interactions by ECIS.
The attachment of MSCs was tested after in vitro induction of dif-
ferentiation into bone or fat tissue. Within 24 h, we were now able to
distinguish different differentiation stages, which also were visualized
by light microscopy in parallel. Specific impedance profiles already
were visible within the first 2 h after starting growth in differentiation
medium. In a ‘‘wound healing assay’’ in the live cell chips, adipogenic
cells showed a reduced migration activity compared to non-differ-
entiated MSCs. With HaCaT keratinocytes, we tested cell attachment
on the level of gene expression. After induction (TetOn system) of the
expression of nidogen, a protein critical for extracellular matrix
384 Genomic Med. (2008) 2:381–388
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formation, cells showed stronger adhesion than without nidogen
expression, which was documented by characteristic impedance
spectra. Compatible RNAi silencing experiments are under way. With
our measurements we are able to discriminate between cell types, cell
densities, and differentiation status. It even is possible to describe the
function of single adhesion molecules. Therefore, this noninvasive
cell-based assay most probably not only will help us to improve
biological resources for advanced cell therapies. Simulation of the
homing process of stem cells in an in vitro assay also is a promising
setup for large-scale gain-of-function or loss-of-function screenings in
functional genomics.
472: Keeping pace with the innovation: an easily
adaptable technique for rapidly generating humanized
animal models in the era of human genome
Subeer S. Majumdar, Suveera Dhup, Abul Usmani,
Mukkesh Gautam, Indrashis Bhattacharya
National Institute of Immunology, Aruna asaf ali marg, New Delhi
110067, India
The phenomenal increase in the amount of information about human
genome is having a huge impact on biomedical research. Transgenic
mice have become invaluable resource and it serves as the most
powerful tool for analysing gene function and regulation in vivo.
Through research utilizing the transgenic mouse or non-human
primate as a model for human disease, investigators can translate
basic biological phenomena into a human health perspective. A
rapid procedure for making transgenic mice is also needed for
screening thousands of human genes whose functions are yet
unknown.
Pronuclear DNA microinjection in the oocyte is the most fre-
quently used technique for generating transgenic animals. This and
other techniques for making transgenic animals are fairly com-
plicated, requiring trained personnel, costly infrastructure and a
large number of zygotes harvested from animals that are then
killed. Due to technical difficulties in obtaining substantial number
of embryos from non-human primates and limitations in repeated
surgical intervention in them, it is practically difficult to make
much needed models of transgenic primates necessary to study
several diseases specific to primates. All these drawbacks generate
a need for developing a handy and cost effective technique for
producing transgenic animals preferably with minimum or no loss
of animal lives. We have developed a reproducible non-terminal
technique for inserting genes in testicular spermatogonial cells
through in vivo electroporation of the testis. The optimal result
was obtained by injecting linearized DNA into the testis of male
mice, followed by electroporation using 8 square 40 V electric
pulses in alternating direction with a time constant of 0.05 s and
an inter pulse interval of *1 s. The transgenesis was confirmed by
PCR, Southern blot analysis and immunohistochemical studies of
the progeny. More than 90% of males electroporated with any one
of the four different constructs successfully sired transgenic pups.
Such electroporated males provide a valuable resource for con-
tinuous production of transgenic founders. This method requires
neither assisted reproductive techniques nor sophisticated labora-
tory setup and highly trained personnel. This ethically superior
(deathless) and easily adaptable time saving procedure opens
avenues for developing several transgenic mice in short span of
time and broadens the scope of making transgenic sub-human
primates. [This study was funded by Department of Biotechnology,
India].
473: Replacing PCR with COLD-PCR enriches variant
DNA sequences and redefines the sensitivity of genetic
testing
Mike Makrigiorgos, Jin Li, Lilin Wang, Harvey Mamon,
Matthew Kulke, Ross Berbeco
Dana Farber Cancer Institute, Harvad Med School, 44 Binney Street,
Boston MA 0215, United States of America
The Polymerase Chain Reaction (PCR) has become the cornerstone of
molecular diagnosis, with almost every genetic test aiming to identify
DNA sequence variation incorporating PCR. A commonly encoun-
tered problem is that variant DNA sequences exist in the presence of a
large majority of wild type alleles such as when DNA is obtained
from heterogeneous cancer biopsies or when fetal alleles are sought in
maternal blood. As a result, downstream assays are severely limited in
their ability to identify subtle genetic changes that can have profound
impact in clinical decision-making and outcome. We describe
Co-amplification at Lower Denaturation temperature (COLD-PCR), a
novel form of PCR that amplifies minority alleles selectively from
mixtures of wild-type and mutation-containing sequences irrespective
of the mutation type or position on the sequence (Technical Report,
Nature Medicine, May 2008 issue). In COLD-PCR, an intermediate
annealing temperature is used during PCR-cycling to allow cross-
hybridization of mutant and wild type alleles; hetero-duplexes, which
melt at lower temperatures than homo-duplexes, are then selectively
denatured and amplified at Critical Denaturation Temperature (Tc),
while homo-duplexes remain double-stranded and do not amplify
efficiently. To validate COLD-PCR, we used serial dilutions of DNA
from tumor-derived cell lines and genomic DNA from a series of
colon and lung cancer surgical specimens, and plasma-circulating
DNA collected under IRB approval were utilized for validation on
clinical specimens. By replacing regular PCR with COLD-PCR prior
to application of a range of assays (Sanger sequencing; Pyrose-
quencing; MALDI-TOF; dHPLC; RFLP; and Taqman) we improved
mutation detection sensitivity up to 100-fold and identified several
additional TP53/KRAS/EGFR mutations in heterogeneous cancer
samples. About 4 of 43 surgical samples and 3 of 10 plasma samples
tested contained clinically important mutations that were not detected
by any of the methods tested when preceded by regular-PCR, but they
were detectable following COLD-PCR. Replacement of regular PCR
with COLD-PCR provides a universal boost to all mutation detection
technologies and enables them to be used with the required confi-
dence in routine screening of cancer specimens for somatic mutations,
including low-level mutation screening of surgical/FFPE tumor
samples or bodily fluids. COLD-PCR is equally applicable to fields
other than cancer, such as pre-natal diagnosis, in infectious diseases
and in epigenetics.
474: A new alternative for two dimensional gel
electrophoresis: OFFGEL electrophoresis combined
with high sensitivity protein sizing on microchips
1Russell McInnes, 2Andreas Ruefer, 2Christian Wenz,
2Tobias Preckel, 2Ruediger Salowsky, 2Martin Greiner
1Agilent Technologies, 347 Burwood Highway, Forest Hill,
Melbourne, VIC 3131, Australia, 2Agilent Technologies, Hewlett
Packard Str.8, 76133 Waldbronn, Germany
In the field of biomarker discovery there is still the need for easy to
use and robust instrumentation that allow reproducible fractionation
of complex protein mixtures with high resolution and highly sensitive
Genomic Med. (2008) 2:381–388 385
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protein detection. Here we present a combination of methods that
separate proteins in analogy to 2 dimensional gel electrophoresis
according to their isoelectric point (pI) and molecular weight. For the
first dimension, OFFGEL electrophoresis was implemented by using
an in-liquid pI fractionation device. This method takes advantage of
the of the high resolving power of gel-immobilized pH gradients but
delivers sample in contrast to conventional isoelectric focusing in
liquid phase. For the second dimension, a new method for high sen-
sitivity analytical protein sizing on microchips was employed. This
technique offers a sensitivity equivalent or better than silver staining
but a linear dynamic range across four orders of magnitude.
475: Anti-Leishmanial Efficacy study of a new
Liposomal Amphotericin B preparation in mouse
model using Quantitative Real Time PCR
Jyotsna Mishra, Ayan Dey, Niti Singh, Sarman Singh
Division of Clinical Microbiology, Department of Laboratory
Medicine, All India Institute of Medical Sciences, New Delhi,
110029, India
In the present study we, for the first time, standardized a quantitative
real time PCR (qRT-PCR) for evaluating the efficacy of new stable
ionic amphiphilic formulation of amphotericin B against visceral
leishmaniasis infection in mice model. BALB/c mice were infected
via tail vein with Leishmania donovani (MHOM/IN/KE16/1998)
promastigotes and after establishment of visceral infection animals
were treated with new liposomal amphotericin B formulation. Using
quantitative Real Time PCR with primers highly specific for the ITS
region of L. donovani we observed the reduction in parasite load from
liver and spleen. This is much more rapid than micro titration assays
or even a conventional PCR. With this technique we were able to
quantify parasite load of even 0.1 parasites per reaction. A dose of 5.0
and 7.5 mg/kg body weight the drug was able to completely clear the
infection from infected mice.
Observations reveal that there is reduction in parasite load by 2 log
unit in liver and spleen compared to untreated, 1 week after last drug
dose was given and finally resulting in complete clearance of parasite.
Leishmania DNA levels vary during and after treatment and their
quantitation using qRT-PCR seems to be useful in real time analysis
of the efficacy of drug.
476: Polymorphism of xenobiotics metabolic genes
and risk prediction: A potential tool for cancer
prevention
Sher Singh Parihar, UK Chauhan
A.P.S. University, Rewa, India
It has been known that most carcinogens require metabolic activation
in the human body for the carcinogenic effects. There are two major
enzyme systems that metabolize potential carcinogens, either syn-
thetic or naturally occurring in human body, which has been classified
as phase I and phase II. Generally, phase I enzymes can activate the
carcinogen directly and produce more active metabolites. Phase II
enzymes can detoxify and process the activated metabolites for final
breakdown or excretion. Therefore, the genetic polymorphism at the
loci encoding Phase I enzymes, such as CYP1A1 and NQO1, and
phase II enzyme GSTM 1 may result in inter-individual variation in
carcinogen metabolism and are related with the origin of high risk
genetic traits or risk population. That’s why it is considered that the
monitoring of carcinogen activating and deactivating gene polymor-
phism can be used in cancer prevention and therapy. In present article
we are presenting the present state of knowledge in the field of genetic
susceptibility and risk prediction.
477: Novel PEI based nanoparticles for delivery
of nucleic acids
Soma Patnaik, Atul Pathak, K. C. Gupta
Institute of Genomics and Integrative Biology, Mall Road, Delhi-7,
India
Gene delivery mediated by polyethyleneimine (PEI) has been widely
investigated as a potential non-viral delivery carrier both in vitro and
in vivo. The application of PEI as a gene carrier, however, is ham-
pered by its inherent charge associated toxicity in the cells. In an
attempt to circumvent the toxicity of PEI and yet maintain the high
transfection efficiency, novel nanoparticles of PEI crosslinked with
hexametaphosphate (P-HMP) were designed and explored in vitro and
in vivo. The size of nanoparticles was found to be less than 200 nm as
deduced by DLS, AFM and TEM studies. Also, all the nanoparticles
carried a positive zeta potential which decreased when complexed to
nucleic acids. The efficacy of nanoparticles to impart protection to
complexed DNA was assessed by treatment with DNase over a period
of 2 h. It was observed that the complexed DNA was conferred a
good protection even after 2 h of treatment with DNase I. Uptake
studies of P-HMP (7.7%) nanoparticles at different time intervals,
based on confocal laser scanning microscopy imaging indicate the
internalization and presence of nanoparticles in the nucleus of cells
after 2 h. The in vitro transfection efficiency of P-HMP nanoparticles
was evaluated in different cell lines and compared with commercial
reagents, Geneporter 2TM, FugeneTM and SuperfectTM. The trans-
fection efficiency of P-HMP (7.7%) was observed to be nearly
1.3–6.4-fold higher as compared to commercial reagents. P-HMP
(7.7%) nanoparticles also efficiently delivered GFP specific siRNA,
resulting in [80% suppression in gene expression in COS-1 cells. the
cell viability profiles of P-HMP nanoparticles/DNA complexes
showed more than 80% cell viability in various mammalian cell lines.
The biodistribution study of labeled P-HMP (7.7%)/DNA complex
was carried out in Balb/c mice. It was found that the labeled P-HMP
(7.7%)/DNA complexes accumulated in almost all the tissues.
Highest retention of the labeled formulation was found to be in liver.
These results signify the application of P-HMP nanoparticles as a
potent delivery agent both in vitro and in vivo.
478: Characterization of whole blood gene expression
profiles in sickle cell disease with enhanced transcript
detection using globin mRNA reduction
1Nalini Raghavachari, 1Xiuli Xu, 2Peter Munson, 3Mark Gladwin
1National Institutes of Health, Bldg 10, 10 Center Dr, Bethesda,
United States of America, 2National Institutes of Health, Bldg 12,
Bethesda, United States of America, 3National Institutes of Health,
CRC, Bethesda, United States of America
Room temperature whole blood mRNA stabilization procedures, such
as the PAX gene system, are critical for the application of tran-
scriptional analysis to population based clinical studies. Global
transcriptome analysis of whole blood RNA using microarrays has
been proven to be challenging due to the high abundance of globin
transcripts that constitute 70% of whole blood mRNA in the blood.
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This is a particular problem in patients with sickle cell disease, sec-
ondary to the high abundance of globin-expressing nucleated red
blood cells and reticulocytes in the circulation. In order to more
accurately measure the steady state whole blood transcriptome in
sickle cell patients we evaluated the efficacy of reducing globin
transcripts in paxgene stabilized RNA samples for genome-wide
transcriptome analyses using oligonucleotide arrays. We demonstrate
here by both microarrays and Q-PCR that the globin mRNA depletion
method resulted in 55–65-fold reduction in globin transcripts in whole
blood collected from healthy volunteers and sickle cell disease
patients. This led to a dramatic improvement in microarray data
quality with increased detection rate of expressed genes and improved
overlap with the expression signatures of isolated peripheral blood
mononuclear (PBMC) preparations. The differentially modulated
genes from the globin depleted samples had a higher correlation
coefficient to the 116 genes identified to be significantly altered in our
previous study on sickle cell disease using PBMC preparations.
Additionally, the analysis of differences between the whole blood
transcriptome and PBMC transcriptome reveals important erythrocyte
genes that participate in sickle cell pathogenesis and compensation.
The combination of globin mRNA reduction after whole-blood RNA
stabilization represents a robust clinical research methodology for the
discovery of biomarkers for hematologic diseases and in multicenter
clinical trials investigating a wide range of nonhematologic disorders
where fractionation of cell types is impracticable.
479: A novel photoreactive heterobifunctional reagent,
1-N-(maleimidohexanoyl)-6-N-(anthraquinon-2-oyl)
hexanediamine (MHAHD) for the preparation
of oligonucleotide microarrays on modified glass
surfaces
D. Sethi, J. Choithani, P. Kumar, K. C. Gupta
Institute of Genomics and Integrative Biology, Mall Road, Delhi,
India
A new heterobifunctional reagent, 1-N-(maleimidohexanoyl)-6-N-
(anthraquinon-2-oyl) hexanediamine (MHAHD), has been developed,
useful for making bioconjugates and immobilization of biomolecules,
viz., oligonucleotides, peptides, proteins, etc., on a variety of carbon-
containing solid surfaces under the influence of light and microwaves.
Its maleimide moiety reacts with mercaptoalkyl functions present in
biomolecules under microwaves, and the anthraquinone structure
reacts with a variety of modified glass surfaces under ultraviolet
irradiation (365 nm). The reagent has been used in two ways. First,
the reagent, MHAHD, was first brought in contact with the modified
glass support and exposed to long wavelength ultraviolet light
(365 nm), thereby generating active maleimidoalkyl functions on the
surface, which later react with appropriate mercaptoalkyl-containing
biomolecules to fix them on the supports under microwaves in just
15 min. In another route, the proposed reagent was allowed to react
first with mercaptoalkylated oligonucleotides to form the appropriate
biomolecule-anthraquinone conjugate, which was then brought in
contact with modified glass microslides, and exposed to ultraviolet
light (365 nm), resulting in immobilization of the conjugates on the
support. Both of the routes work satisfactorily and we could suc-
cessfully immobilize a number of modified oligonucleotides on a
modified glass surface. The oligonucleotide arrays produced by both
the routes were analyzed by hybridization experiments (hybridization
efficiency 30.13%) and subsequently used for the discrimination of
base mismatches. The constructed microarrays were found to possess
good thermal stability (only 4.5% loss of fluorescence intensity
observed after ten cycles).
480: MetaBioME: comprehensive metagenomic
BioMining engine to search novel biocatalysts
in metagenomic datasets
Vineet K. Sharma, Naveen Kumar, Tulika Prakash, Todd D. Taylor
MetaSystems Research Team, Advanced Science Institute, RIKEN,
W403, West Bldg., 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama,
Kanagawa, 230-0045, Japan
Microbial enzymes or biocatalysts offer ecologically friendly or
‘green’ solutions for cost-effective implementation of biochemical
processes which produces a large variety of chemical substances used
in areas like industry, biotechnology, agriculture, pharmaceutics, etc.
However, only a few enzymes are currently employed for such
applications due to the limited number of sequenced microbes, which
is principally limited by the fact that most ([98%) of the microbes
cannot be cultured, a necessary step for their sequencing by tradi-
tional methods. This yet unculturable majority of microbes conceal an
enormous treasure of unknown biological functions locked in their
hereunto unidentified genes, proteins and biochemical pathways
which can enrich life sciences, industry, biotechnology and human
health. In this scenario, metagenomics has emerged as a powerful
culture-independent approach for exploring the complexity of
microbial genomes in their natural environments. Therefore, to har-
ness the potential of metagenomic information, we used our in-house
developed computational resource ‘iMetaSys’ to carry out the com-
prehensive mining of ten diverse publicly available metagenomic
datasets. Using available information, we curated a dataset of *500
known biocatalysts and classified them into nine broad application
categories namely Agriculture, Biotechnology, Energy, Industry,
Medicare, Environment, Nutrition, Enzymatic Analysis and General
Applications. We mined the metagenomic datasets for these bio-
catalysts and identified several novel biocatalysts which could be used
as alternatives to the existing ones. Using this strategy, we developed
the comprehensive Metagenomic BioMining Engine (MetaBioME)
platform to facilitate the computational identification and validation
of commercially useful novel biocatalysts from metagenomic datasets
and to carry out more advanced analyses. The main features of
MetaBioME and a summary of the work will be presented.
481: ‘Universal’ control assay selection and evaluation
using comparative genomics approach for copy number
variation detection
Chunlin Xiao, Kelly Li, Yu Wang, Adam Broomer, Caifu Chen,
Eugene Spier
Applied Biosystems, 45 West Gude Drive, Rockville, MD 20850,
United States of America
The importance of copy number variations (CNVs) in human genome
has been demonstrated in recent publications, and various technolo-
gies, including TaqMan real-time PCR assays, have been developed
for detecting copy number variations. One of the challenges for
accurately determining the gene copy number in a given sample is to
use an appropriate control or reference assay for normalization in
TaqMan copy number assays. The quality of control assay will
significantly affect the accuracy of copy number calling. In order to
minimize the variability of control assay across populations and
species, the target sequences of control/reference assay should pos-
sess the following properties: (1) exact two copies in diploid genome;
(2) extremely conserved in reference genome and other mammalian
genomes; (3) not located in regions with highly genome
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rearrangement activities such as CNVs, indels, inversions, and seg-
mental duplications, or with abundant genetic variations such as
SNPs; (4) not susceptible to the diseases; (5) optimal sequence
thermodynamics and compositions for TaqMan assay design. To
achieve such goals, we use a comparative genomics approach to
select 42 candidate target sequences with high quality from multiple
species including human, chimpanzee, rhesus monkey, mouse, and rat
for control/reference assay design. Those newly defined control/ref-
erence assays have been tested in various samples, and their
performances have been carefully evaluated. The top five control
assays are suggested as ‘universal’ for copy number detection in
multiple species using TaqMan real-time PCR technology.
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